Suppression of the cytotoxicity and fibrogenicity of silica with PVPNO.
Silica and silica-induced lung diseases. Castranova V, Vallyathan V, Wallace WE, eds. Boca Raton, FL: CRC Press, 1995 Dec; :293-298
This report reviewed data supporting the effectiveness of polyvinylpyridine-N-oxide (PVPNO) in decreasing the cytotoxicity of silica (14808607) in-vitro and its fibrogenicity in-vivo. PVPNO administered to laboratory animals was effective in diminishing adverse pulmonary reactions to silica. PVPNO can be administered subcutaneously, intravenously, or by inhalation. Positive effects were noted when PVPNO was administered prior to, during, or months after silica exposure. Evidence was noted that the protective action may be compromised as the period between silica exposure and subsequent treatment becomes greater. Protection may also dissipate with time following discontinuation of PVPNO therapy. Adverse effects such as cirrhosis and tumors have been discussed. A number of clinical studies suggested that PVPNO may exert a positive therapeutic action in workers with various degrees of silicosis. The action was thought to be due to the ability of PVPNO to strongly bind to surface silanol groups on alpha-quartz. Treatment of animals appeared to prevent the onset or progression of silicosis. Clinical trials to date may have lacked properly matched control groups, and lack of control of radiograph and reader quality may have affected these studies.
Respiratory-system-disorders; Silicosis; Medical-treatment; Laboratory-animals; Liver-damage; Carcinogens; Lung-irritants; Silica-dusts
Castranova-V; Vallyathan-V; Wallace-WE
Silica and silica-induced lung diseases